Schizophrenia trials are subject to multiple endpoint comparison problems, the risk of false-positives, patient non-compliance, high drop-out rates and missing data. Stroup and colleagues discuss current trial limitations and how these might be addressed by innovations in trial design and statistics.
- T. Scott Stroup
- Wayne M. Alves
- Jeffrey A. Lieberman
